Operating Income for IDEXX Laboratories (IDXX)
According to IDEXX Laboratories's latest reported financial statements, the company's current operating income (TTM) is $1.36B USD. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingOperating IncomeSwitch metric
TTM (last 4 quarters)
$1.36B
YoY change
+20.5%
5Y CAGR
+14.4%
Peak year (2025)
$1.36B
Cumulative operating income
$10.74B
Operating Income history chart for IDEXX Laboratories (IDXX) from 1991 to 2025
Operating Income history table for IDEXX Laboratories (IDXX) from 1991 to 2025
| Fiscal year | Period ended | Reported | Operating Income | YoY |
|---|---|---|---|---|
| 2025 | $1.36B | +20.5% | ||
| 2024 | $1.13B | +2.8% | ||
| 2023 | $1.10B | +22.1% | ||
| 2022 | $898.76M | -3.6% | ||
| 2021 | $932.03M | +34.2% | ||
| 2020 | $694.52M | +25.6% | ||
| 2019 | $552.85M | +12.5% | ||
| 2018 | $491.33M | +19.0% | ||
| 2017 | $413.03M | +17.9% | ||
| 2016 | $350.24M | +16.8% | ||
| 2015 | $299.91M | +15.2% | ||
| 2014 | $260.25M | -2.4% | ||
| 2013 | $266.76M | +1.6% | ||
| 2012 | $262.56M | +11.1% | ||
| 2011 | $236.22M | +15.9% | ||
| 2010 | $203.88M | +15.9% | ||
| 2009 | $175.97M | +2.0% | ||
| 2008 | $172.46M | +26.6% | ||
| 2007 | $136.18M | +6.4% | ||
| 2006 | $127.93M | +10.9% | ||
| 2005 | $115.33M | +6.8% | ||
| 2004 | $108.03M | +34.4% | ||
| 2003 | $80.39M | +22.1% | ||
| 2002 | $65.81M | +16.4% | ||
| 2001 | $56.55M | +6.2% | ||
| 2000 | $53.25M | +13.8% | ||
| 1999 | $46.80M | +60.8% | ||
| 1998 | $29.10M | -761.4% | ||
| 1997 | -$4.40M | -109.4% | ||
| 1996 | $47.00M | +42.9% | ||
| 1995 | $32.90M | +44.3% | ||
| 1994 | $22.80M | +64.0% | ||
| 1993 | $13.90M | +172.5% | ||
| 1992 | $5.10M | +96.2% | ||
| 1991 | $2.60M | — |
Operating Income values are taken from IDEXX Laboratories's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
The 2025 reading of IDEXX Laboratories (IDXX) operating income is $1.36B – grew 20.5% year-over-year.
Through 2020–2025 (5 years), IDEXX Laboratories operating income delivered a +14.4% annualised rate; sustaining 3 straight years of year-over-year growth.
Across the available history, operating income reached its high of $1.36B in 2025 and its low of -$4.40M in 1997.
Within Healthcare, IDEXX Laboratories (IDXX) ranks 9th among 8 peers we track. The peer median for operating income is $22.84B.
IDEXX Laboratories Operating Income by Year
IDEXX Laboratories Operating Income 2025: $1.36B
IDEXX Laboratories operating income in 2025 was $1.36B, grew 20.5% from 2024. This figure represents the highest annual value in the available history.
IDEXX Laboratories Operating Income 2024: $1.13B
IDEXX Laboratories operating income in 2024 was $1.13B, edged up 2.8% from 2023.
IDEXX Laboratories Operating Income 2023: $1.10B
IDEXX Laboratories operating income in 2023 was $1.10B, grew 22.1% from 2022.
IDEXX Laboratories Operating Income 2022: $898.76M
IDEXX Laboratories operating income in 2022 was $898.76M, edged down 3.6% below 2021.
IDEXX Laboratories Operating Income 2021: $932.03M
IDEXX Laboratories operating income in 2021 was $932.03M.
See more financial history for IDEXX Laboratories (IDXX).
Sector peers — Operating Income
Companies in the same sector as IDEXX Laboratories, ranked by their latest operating income.
| Company | Operating Income | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $127.66B | Healthcare |
| Eli Lilly and Company (LLY) | $29.70B | Healthcare |
| Merck & Co., Inc. (MRK) | $26.78B | Healthcare |
| Johnson & Johnson (JNJ) | $25.60B | Healthcare |
| AbbVie Inc. (ABBV) | $20.09B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $18.96B | Healthcare |
| AstraZeneca PLC (AZN) | $13.74B | Healthcare |
| Amgen Inc. (AMGN) | $10.68B | Healthcare |
Frequently asked questions
What is IDEXX Laboratories's operating income?
- Latest reported operating income for IDEXX Laboratories (IDXX) is $1.36B (period ending December 31, 2025).
How has IDEXX Laboratories operating income changed year-over-year?
- IDEXX Laboratories (IDXX) operating income changed +20.5% year-over-year on the latest annual filing.
What is the long-term growth rate of IDEXX Laboratories operating income?
- IDEXX Laboratories (IDXX) operating income compound annual growth rate is +14.4% over the most recent 5 years available.
When did IDEXX Laboratories operating income hit its highest annual value?
- IDEXX Laboratories operating income reached its highest annual value of $1.36B in 2025.
What was IDEXX Laboratories operating income in 2024?
- IDEXX Laboratories (IDXX) operating income in 2024 was $1.13B.
What was IDEXX Laboratories operating income in 2025?
- IDEXX Laboratories (IDXX) operating income in 2025 was $1.36B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
IDXX Overview
Company profile, financial tools, and key metrics
IDXX Revenue Counter
Earns $136.47 every second. See per minute, hour, and day.
IDXX Earnings Counter
Earns $33.60 per second net profit. See per minute, hour, and day.
IDXX Economic Scale
Exceeds Aruba's GDP. Compare with world economies.
IDXX What If Invested
What if you had invested $1,000? See historical returns from any date.
IDXX How It Makes Money
Discover visual breakdown of $4.30B in revenue — where it comes from and where it goes.
IDXX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
IDXX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
IDXX Daily Price Character
Explosive · 50.9% historical win rate (green days). Streaks & record days.
IDXX Buybacks
2.25% TTM buyback yield. Shareholder yield & SBC comparison.
IDXX Stock Split History
4 splits on record. Dates, ratios, and cumulative multiple.